Dynavax Technologies Corporation (DVAX)
USD 10.39
(-2.44%)
USD 10.39
(-2.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 182.11 Million USD | -60.45% |
| 2022 | 460.53 Million USD | 73.22% |
| 2021 | 265.87 Million USD | 714.53% |
| 2020 | 32.64 Million USD | 106.2% |
| 2019 | 15.83 Million USD | 216.41% |
| 2018 | -13.59 Million USD | -1468.4% |
| 2017 | -867 Thousand USD | -107.85% |
| 2016 | 11.04 Million USD | 172.67% |
| 2015 | 4.05 Million USD | -63.29% |
| 2014 | 11.03 Million USD | -1.95% |
| 2013 | 11.25 Million USD | 15.82% |
| 2012 | 9.71 Million USD | -54.43% |
| 2011 | 21.31 Million USD | -7.21% |
| 2010 | 22.97 Million USD | -41.61% |
| 2009 | 39.33 Million USD | 8.93% |
| 2008 | 36.11 Million USD | 175.91% |
| 2007 | 13.08 Million USD | 215.47% |
| 2006 | 4.14 Million USD | -71.69% |
| 2005 | 14.65 Million USD | -1.06% |
| 2004 | 14.81 Million USD | 1693.22% |
| 2003 | 826 Thousand USD | -42.12% |
| 2002 | 1.42 Million USD | -39.51% |
| 2001 | 2.35 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 61.81 Million USD | 55.21% |
| 2024 Q1 | 39.82 Million USD | -15.1% |
| 2023 Q2 | 46.71 Million USD | 45.01% |
| 2023 Q1 | 32.21 Million USD | -69.9% |
| 2023 Q4 | 46.9 Million USD | -16.66% |
| 2023 Q3 | 56.28 Million USD | 20.49% |
| 2023 FY | 182.11 Million USD | -60.45% |
| 2022 Q2 | 173.09 Million USD | 133.82% |
| 2022 FY | 460.53 Million USD | 73.22% |
| 2022 Q4 | 107 Million USD | 0.57% |
| 2022 Q3 | 106.4 Million USD | -38.53% |
| 2022 Q1 | 74.03 Million USD | -38.85% |
| 2021 Q3 | 48.18 Million USD | 27.05% |
| 2021 Q2 | 37.92 Million USD | -35.41% |
| 2021 Q4 | 121.05 Million USD | 151.26% |
| 2021 Q1 | 58.71 Million USD | 278.97% |
| 2021 FY | 265.87 Million USD | 714.53% |
| 2020 Q3 | 9.38 Million USD | 525.95% |
| 2020 Q2 | 1.49 Million USD | -76.08% |
| 2020 FY | 32.64 Million USD | 106.2% |
| 2020 Q4 | 15.49 Million USD | 65.11% |
| 2020 Q1 | 6.26 Million USD | 7.31% |
| 2019 FY | 15.83 Million USD | 216.41% |
| 2019 Q1 | 1.7 Million USD | 24.18% |
| 2019 Q2 | 3.86 Million USD | 127.24% |
| 2019 Q3 | 4.42 Million USD | 14.6% |
| 2019 Q4 | 5.84 Million USD | 31.92% |
| 2018 Q3 | -6.28 Million USD | -1.09% |
| 2018 FY | -13.59 Million USD | -1468.4% |
| 2018 Q1 | -2.45 Million USD | -109.46% |
| 2018 Q2 | -6.22 Million USD | -153.19% |
| 2018 Q4 | 1.36 Million USD | 121.77% |
| 2017 Q2 | 105 Thousand USD | -29.05% |
| 2017 FY | -867 Thousand USD | -107.85% |
| 2017 Q4 | -1.17 Million USD | -2313.21% |
| 2017 Q3 | 53 Thousand USD | -49.52% |
| 2017 Q1 | 148 Thousand USD | -97.97% |
| 2016 Q1 | 942 Thousand USD | 37.52% |
| 2016 Q2 | 2.64 Million USD | 181.0% |
| 2016 Q4 | 7.29 Million USD | 4401.23% |
| 2016 Q3 | 162 Thousand USD | -93.88% |
| 2016 FY | 11.04 Million USD | 172.67% |
| 2015 Q1 | 627 Thousand USD | -72.46% |
| 2015 Q2 | 1.55 Million USD | 147.21% |
| 2015 Q4 | 685 Thousand USD | -42.34% |
| 2015 Q3 | 1.18 Million USD | -23.35% |
| 2015 FY | 4.05 Million USD | -63.29% |
| 2014 FY | 11.03 Million USD | -1.95% |
| 2014 Q4 | 2.27 Million USD | 3.08% |
| 2014 Q1 | 3.49 Million USD | 22.87% |
| 2014 Q2 | 3.04 Million USD | -12.86% |
| 2014 Q3 | 2.2 Million USD | -27.53% |
| 2013 Q3 | 2.92 Million USD | -13.71% |
| 2013 Q4 | 2.84 Million USD | -2.73% |
| 2013 Q1 | 2.08 Million USD | 15.45% |
| 2013 FY | 11.25 Million USD | 15.82% |
| 2013 Q2 | 3.39 Million USD | 62.69% |
| 2012 Q3 | 2.87 Million USD | 7.08% |
| 2012 Q2 | 2.68 Million USD | 14.21% |
| 2012 Q1 | 2.35 Million USD | -78.88% |
| 2012 FY | 9.71 Million USD | -54.43% |
| 2012 Q4 | 1.8 Million USD | -37.16% |
| 2011 FY | 21.31 Million USD | -7.21% |
| 2011 Q4 | 11.12 Million USD | 847.87% |
| 2011 Q1 | 1.49 Million USD | 90.71% |
| 2011 Q2 | 7.21 Million USD | 381.32% |
| 2011 Q3 | 1.17 Million USD | -83.73% |
| 2010 Q3 | 11.4 Million USD | 486.02% |
| 2010 Q1 | 8.09 Million USD | 569.89% |
| 2010 Q2 | 1.94 Million USD | -75.97% |
| 2010 FY | 22.97 Million USD | -41.61% |
| 2010 Q4 | 786 Thousand USD | -93.11% |
| 2009 Q4 | 1.2 Million USD | -54.48% |
| 2009 FY | 39.33 Million USD | 8.93% |
| 2009 Q3 | 2.65 Million USD | -83.02% |
| 2009 Q2 | 15.63 Million USD | -18.12% |
| 2009 Q1 | 19.09 Million USD | 74.18% |
| 2008 Q2 | 9.73 Million USD | 60.37% |
| 2008 Q1 | 6.06 Million USD | -40.93% |
| 2008 FY | 36.11 Million USD | 175.91% |
| 2008 Q4 | 10.96 Million USD | 27.32% |
| 2008 Q3 | 8.61 Million USD | -11.52% |
| 2007 Q4 | 10.27 Million USD | 1246.66% |
| 2007 Q3 | 763 Thousand USD | -50.71% |
| 2007 Q2 | 1.54 Million USD | -10.68% |
| 2007 Q1 | 1.73 Million USD | -0.4% |
| 2007 FY | 13.08 Million USD | 215.47% |
| 2006 Q1 | 288 Thousand USD | -52.0% |
| 2006 Q2 | 529 Thousand USD | 83.68% |
| 2006 FY | 4.14 Million USD | -71.69% |
| 2006 Q3 | 1.34 Million USD | 153.5% |
| 2006 Q4 | 1.74 Million USD | 29.75% |
| 2005 Q3 | 404 Thousand USD | -57.61% |
| 2005 Q4 | 600 Thousand USD | 48.51% |
| 2005 FY | 14.65 Million USD | -1.06% |
| 2005 Q1 | 12.69 Million USD | 417.23% |
| 2005 Q2 | 953 Thousand USD | -92.49% |
| 2004 Q3 | 3.66 Million USD | -33.36% |
| 2004 Q4 | 2.45 Million USD | -32.92% |
| 2004 Q1 | 3.2 Million USD | 353.32% |
| 2004 FY | 14.81 Million USD | 1693.22% |
| 2004 Q2 | 5.49 Million USD | 71.36% |
| 2003 FY | 826 Thousand USD | -42.12% |
| 2003 Q2 | 96 Thousand USD | 0.0% |
| 2003 Q3 | 23 Thousand USD | -76.04% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | 707 Thousand USD | 2973.91% |
| 2002 FY | 1.42 Million USD | -39.51% |
| 2001 FY | 2.35 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 44.165% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -32774.826% |
| Embecta Corp. | 749.9 Million USD | 75.714% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 62.857% |
| PainReform Ltd. | -15 Thousand USD | 1214213.333% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -2083.874% |
| SCYNEXIS, Inc. | 124.51 Million USD | -46.259% |
| Journey Medical Corporation | 52.52 Million USD | -246.751% |
| Safety Shot Inc | -74.45 Thousand USD | 244693.524% |
| Alpha Teknova, Inc. | 10.29 Million USD | -1668.813% |
| Bright Green Corporation | -237.01 Thousand USD | 76937.429% |
| Procaps Group, S.A. | 239.56 Million USD | 23.981% |
| Alvotech | -69.42 Million USD | 362.333% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 40.349% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -512.117% |
| Cosmos Health Inc. | 4.34 Million USD | -4087.013% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -149.247% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 57.709% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -2083.874% |
| Theratechnologies Inc. | 62.12 Million USD | -193.127% |
| Harrow Health, Inc. | 90.55 Million USD | -101.116% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -3738.082% |
| Biofrontera Inc. | 16.62 Million USD | -995.309% |
| DURECT Corporation | 6.83 Million USD | -2566.037% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 65.228% |
| Cronos Group Inc. | 6.99 Million USD | -2505.059% |
| OptiNose, Inc. | 62.35 Million USD | -192.069% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 58.719% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 60204.62% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -5862.891% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 41.213% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -3275.965% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -443.862% |
| Radius Health, Inc. | 307.71 Million USD | 40.816% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -1707.096% |
| ProPhase Labs, Inc. | 16.23 Million USD | -1021.479% |
| Phibro Animal Health Corporation | 312.48 Million USD | 41.72% |
| Procaps Group S.A. | 239.56 Million USD | 23.981% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -13887.481% |
| Viatris Inc. | 6.43 Billion USD | 97.171% |
| Rockwell Medical, Inc. | 8.7 Million USD | -1992.337% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -233.633% |
| SIGA Technologies, Inc. | 122.09 Million USD | -49.164% |
| Tilray Brands, Inc. | 223.35 Million USD | 18.462% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -335.166% |
| Shineco, Inc. | 882.16 Thousand USD | -20544.254% |
| PetIQ, Inc. | 252.74 Million USD | 27.943% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 24525.956% |
| Incannex Healthcare Limited | 12 Thousand USD | -1517541.667% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 90.142% |
| Alimera Sciences, Inc. | 61.17 Million USD | -197.723% |
| Silver Spike Investment Corp. | 8.1 Million USD | -2147.637% |
| Assertio Holdings, Inc. | 125.04 Million USD | -45.637% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 2673965.805% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -4245.257% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -2677.868% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 7656.17% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -571.597% |
| Hempacco Co., Inc. | -1.21 Million USD | 15078.784% |
| Talphera, Inc. | -4.89 Million USD | 3820.47% |
| Alvotech | -69.42 Million USD | 362.333% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 17.845% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 74.333% |
| Currenc Group, Inc. | 17.35 Million USD | -949.284% |
| Kamada Ltd. | 52.59 Million USD | -246.278% |
| Indivior PLC | 907 Million USD | 79.921% |
| Evoke Pharma, Inc. | 4.97 Million USD | -3557.885% |
| Flora Growth Corp. | 17.73 Million USD | -926.705% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 7656.17% |
| Evolus, Inc. | 140.52 Million USD | -29.597% |
| HUTCHMED (China) Limited | 453.55 Million USD | 59.847% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 47.054% |
| Akanda Corp. | 111.44 Thousand USD | -163308.375% |